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Effect of methotrexate/vitamin B12 on DNA
methylation as a potential factor in leukemia
treatment-related neurotoxicity
Victoria J Forster*,1, Alex McDonnell2, Rachel Theobald2 & Jill A McKay2
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
2Institute of Health & Society, Human Nutrition Research Centre, Newcastle University, Newcastle upon Tyne, UK
* Author for correspondence: victoria.forster@sickkids.ca
Methotrexate (MTX) is administered to treat childhood acute lymphoblastic leukemia (ALL). It acts by
inhibiting dihydrofolate reductase which reduces methyltetrahydrofolate, a key component in one car-
bon metabolism, thus reducing cell proliferation. Further perturbations to one carbon metabolism, such
as reduced vitamin B12 levels via the use of nitrous oxide for sedation during childhood ALL treatment,
may increase neurotoxicity risk. With B12 as an enzymatic cofactor, methyltetrahydrofolate is essential
to produce methionine, which is critical for DNA methylation. We investigated global and gene specific
DNA methylation in neuronal cell lines in response to MTX treatment and vitamin B12 concentration indi-
vidually, and in combination. Results: MTX treatment alone significantly increased LINE-1 methylation in
SH-SY5Y (p = 0.040) and DAOY (p < 0.001), and increased FKBP5 methylation in MO3.13 cells (p = 0.009).
Conclusion: We conclude that altered DNA methylation of brain/central nervous system cells could be
one mechanism involved in MTX treatment-related neurotoxicities and neurocognitive late effects in ALL
survivors.
First draft submitted: 26 November 2016; Accepted for publication: 21 June 2017; Published online: 15
August 2017
Keywords: childhood acute lymphoblastic leukemia • epigenetic • late effects • methotrexate • neurocognition •
neurotoxicity • one carbon metabolism • vitamin B12
One carbon metabolism, which is driven by dietary B vitamins folate, B2, B6 and B12, is integral to DNA synthesis
and themethylation of biological molecules includingDNA (Figure 1) [1]. Disruption of this metabolic pathway can
therefore inhibit cell proliferation,making this pathway an ideal target for cancer treatments.Methotrexate (MTX) is
an antifolate drug, frequently administered to treat many types of cancers, including childhood acute lymphoblastic
leukemia (ALL) and some autoimmune disorders such as arthritis. It inﬂuences one carbon metabolism (OCM) by
reducing levels of tetrahydrofolate (THF) via inhibition of dihydrofolate reductase, thus reducing the production
of S-adenosylmethionine (SAM), which is critical for DNA synthesis and methylation (Figure 1).
In childhood leukemia patients, MTX treatment has been associated with acute neurotoxicities [2,3] (which in
extreme cases can manifest in stroke-like symptoms) and long term [4,5] neurological issues. Furthermore, it has
been noted that the use of nitrous oxide (N2O) in sedation during or shortly prior to administration of MTX
may contribute to the risk of severe acute neurological side effects in children with acute leukemia when MTX is
administered intrathecally [3]. Since, N2O depletes active vitamin B12, which is an essential cofactor in OCM, this
suggests that inhibition of OCM via multiple routes in other words combined MTX treatment and N2O use, may
have a synergistic effect [6] and increase the risk of neurotoxcity in comparison with the use of either agent alone.
Indeed, in rats high dose MTX concomitant with N2O exposure resulted in toxicity [7]. Furthermore, a recent
meta-analysis reported a signiﬁcant association of the C677T polymorphism of the methylene tetrahydrofolate
reductase gene which is responsible for the conversion of 5′10 methyltetrahydrofolate (MTHF) to MTHF in
OCM, with overall MTX toxicity, hepatotoxicity, hematological toxicity and neurotoxicity [8]. Currently, the
underlying biological mechanisms behind these associations are unknown.
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Figure 1. Summary diagram of the main pathways involved in cellular one-carbon metabolism including the
production of S-adenosylmethionine for methylation of DNA. Dietary factors able to influence this pathway are
highlighted in red, enzymes driving biological reactions are highlighted in blue/bold. The influence of methotrexate
on this pathway through the inhibition of dihydrofolate reductase enzyme is highlighted in red/italics. Additional
abbreviations: DHF, THF, SHMT, MTRR, MTHFR, BHMT, CBS, COMT, DNMT, SAH.
BHMT: Betaine-homocysteine S-methyltransferase; CBS: Cystathione beta synthase; COMT: cystathionine beta
synthase; DHF: Dihydrofolate; DHFR: Dihydrofolate reductase; DNMT: DNA methyltransferase;
MTHFR: Methylenetetrahydrofolate reductase; MTRR: Methionine synthase reductase; MTX: Methotrexate;
SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; SHMT: Serine hydroxymethyltransferase;
THF: Tetrahydrofolate.
Modified with permission from [1] (2011).
DNA methylation, (addition of a methyl group to cytosine followed by guanine [CpG sites]), is one mechanism
of gene regulation. It is generally accepted that methylation of CpG rich regions inhibits binding of the regulatory
machinery, leading to gene silencing. Consequently gene dysregulation via aberrant DNA methylation may be an
important contributor to disease. Also, while the DNA sequence is generally more resistant to change in response to
noncarcinogenic environmental factors, DNA methylation is more plastic and is altered more easily by a variety of
more subtle exposures [9]. Evidence suggests that DNA methylation may play an important role in neurotoxicities
such as cognitive impairments (reviewed in [10]). In addition, DNA methylation has recently been suggested to
play a key role in gene regulation during peripheral nerve myelination [11]. Malformation or destruction of myelin
sheaths leads to motor and sensory disabilities, suggesting a potential role for DNA methylation in neurological
disorders [12]. Furthermore, MTX treatment has been reported to alter DNA methylation in patients being treated
for arthritis [13–15]. We therefore, hypothesize that DNA methylation may be one potential mediating mechanism
linking MTX treatment with increased risk of neurotoxicity. Furthermore, we suggest that vitamin B12 levels may
inﬂuence the effect MTX treatment has on DNA methylation patterns.
To test the initial hypothesis that MTX and B12 treatments may have the potential to alter DNA methylation
in cell lines derived from cell populations which maybe relevant for neurotoxicity, we used a 3 × 3 factorial study
design we treated neuronal and oligodendrocyte cell lines with varying concentrations ofMTX in combination with
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Figure 2. Schema depicting 3 × 3 factorial study
design. The experiment was carried out in triplicate for
each cell line, resulting in an n = 9 per group to
investigate the main effects of MTX and vitamin B12
treatments alone, and n = 3 to investigate the
interaction between treatments.
MTX: Methotrexate.
different concentrations of vitamin B12. After 3 days exposure we harvested cells for DNA extraction to measure
both global and gene speciﬁc DNA methylation in response to treatments.
Materials & methods
Cell lines & tissue culture
Oligodendrocytic MO3.13 (Cedarlane Laboratories, Canada), medulloblastoma DAOY and neuroblastoma SH-
SY5Y cell lines (ATCC,Middlesex, UK) were all cultured inDMEMhigh glucose (Sigma) with 10%of dialysed fetal
bovine serum (dFBS) and 1% penicillin/streptomycin solution (Sigma). Dialyzed FBS (ThermoFisher Scientiﬁc) is
depleted of small molecules (less than 10 kDa) including vitamin B12, allowing for more deﬁned culture conditions
than with conventional FBS, where components can be reintroduced as required. Cells were routinely passaged
every 2–3 days when reaching 80–90% conﬂuence. Brieﬂy, all media were removed from culture vessels and
cells were washed once with prewarmed PBS. The 1× trypsin (Sigma), diluted in PBS was added and cells were
incubated at 37◦C for 5 min to detach them from the plastic. Flask was tapped gently to detach cells and growth
medium was immediately added before gently pipetting cells up and down to create a single-cell suspension before
quantiﬁcation of cell number.
Methotrexate & vitamin B12 treatment of cells for proliferation analysis
To ensure selected doses ofMTX reduced proliferation in all three-cell lines, initial growth proliferation experiments
were performed. MO3.13, DAOY and SH-SY5Y were seeded in T25 cm2 ﬂasks at the following densities (total
cell number): MO3.13 and DAOY; 1 × 105 - SH-SY5Y - 2 × 105. In a 3 × 3 factorial design, cells were treated
with various concentrations of vitamin B12 (Sigma) (0, 1 and 10 ng/ml ﬁnal concentration in culture media) at the
time of seeding and left to adhere overnight before a single dose treatment with either 0, 1 or 5 μM MTX (Sigma),
resulting in nine overall treatment groups (see Figure 2). The experiment was carried out in triplicate for each cell
line, resulting in an n = 9 per group to investigate the main effects of MTX and vitamin B12 treatments alone, and
n = 3 to investigate the interaction between treatments (Figure 2). Both MTX and vitamin B12 were resuspended
in molecular grade water. MTX was incubated with the cells for the remainder of the culture period of 3 days, at
37◦C in a 5% CO2 incubator before quantifying cells with a hemocytometer.
Quantification of cells using a hemocytometer
Cells were quantiﬁed using a counting chamber (Nebauer) after mixing in a 1:1 ratio with trypan blue (Sigma) to
exclude dead cells. The average of two separate counts was taken to calculate cell number.
Methotrexate & vitamin B12 treatment of cells for methylation analysis
Cells were seeded at higher densities proportional to the original growth proliferation experiments in order to ensure
adequate DNA for methylation assays in T175 cm2 ﬂasks at the following starting densities (total cell number):
MO3.13 and DAOY; 7 × 105 – SH-SY5Y – 14 × 105 cells were treated with MTX and B12 at the same ﬁnal
concentrations and under the same conditions as detailed above. Three days post MTX dosing, cells were washed
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twice in ﬂasks with PBS, detached using 1× trypsin in PBS, followed by inactivating trypsin with 1 ml of DMEM
10% media (detailed above), centrifuged at 300 × g for 5 min and then proceeding to DNA extraction. The
experiment was carried out in triplicate for each cell line, resulting in an n = 9 per group to investigate the main
effects of MTX and vitamin B12 treatments alone, and n = 3 to investigate the interaction between treatments
(Figure 2).
DNA extraction, bisulphite modification & DNA methylation assessment using pyrosequencing
DNA was extracted and puriﬁed from cell pellets using the using an EZNA tissue DNA isolation kit (Omega
Biotek) as detailed in manufacturer’s protocol. DNA purity and concentration was determined using a Nanodrop
Spectrophotometer (ThermoScientiﬁc).
Bisulﬁte conversion of DNA was performed using EZ DNA Methylation GoldTM kit (Zymo Research) as
detailed in manufacturers’ protocol. Brieﬂy, 1 μg of genomic DNA was incubated with CT conversion reagent and
incubated at the following temperatures; 98◦C for 10 min, 64◦C for 2.5 h, held at 4◦C. DNA was then transferred
to a spin column, washed, desulphonated and puriﬁed, ﬁnally eluting in a 12 μl volume of elution buffer and
stored routinely at -20◦C.
We used quantitative bisulﬁte pyrosequencing to determine the percentage methylation at individual CpG sites
within the LINE1 [16],HOXA4 [17] and FKBP5 loci. LINE1methylation was investigated as a proxy for genome-wide
methylation changes [16].HOXA4methylation was investigated as increased methylation at this locus has previously
been observed in response to exposure to therapy in acute lymphoblastic leukemia patients [18] and therefore
methylation at this loci may be altered in response to MTX treatment. HOXA4 methylation was measured +32 to
+219 bp upstream of the transcriptional start site within a CpG island spanning the transcriptional start site, with
methylation of this region previously having been associated with loss of gene expression [17]. FKBP5 methylation
was investigated as this gene is known to exhibit altered DNA methylation in abused children and to be associated
with adult onset depression [19] an adverse effect associated with childhood cancer [20–22]. Methylation of FKBP5
was measured at a glucocorticoid responsive element in intron seven of the gene. While there have been no reports
of altered methylation at this region being associated with altered expression of the gene itself, demethylation in
this region has been reported to increase stress dependant gene transcription leading to long-term dysregulation of
glucocorticoid regulation [19]. Brieﬂy, 1 μl of bisulﬁte treated DNA was added as a template in PCR reaction using
either 10 or 12.5 μl Hot Star Taq mastermix (Qiagen), in a total volume either 20 or 25 μl, respectively. All primer
sequences and PCR conditions are shown in Table 1. Ampliﬁcation was carried out in either a ThermoHybaid
PxE0.2 (ThermoScientiﬁc) or Veriti (Applied Biosystems) 96 well Thermal Cycler using the following protocol
for LINE1; 95◦C 15 min, then 50 cycles of 95◦C 15 s, annealing temperature 30 s, 72◦C 15 s, followed by 72◦C
for 5 min, or 95◦C 15 min, then 40 cycles of 95◦C 30 s, annealing temperature 30 s, 72◦C 1 min, followed by
72◦C for 7 min for HOXA4 and FKBP5 respectively. Biotin-labeled PCR products were captured with Streptavidin
Sepharose beads (GE Healthcare), and made single stranded using a Pyrosequencing Vacuum Prep Tool (Qiagen).
Sequencing primers were annealed to the single stranded PCR product by heating to 80◦C, followed by slow
cooling. Pyrosequencing was then carried out on a Pyromark MD system. Cytosine methylation was quantiﬁed by
the Pyro Q CpG 1.0.6 software.
Statistical analysis
Analysis of variance was used to examine the main effects of MTX treatment and vitamin B12 concentration, and
the interaction between these treatments on cell proliferation and mean DNA methylation for individual genes
(calculated as a mean methylation value across the analyzed CpG site for each gene loci; 3 CpGs for LINE1, 4
CpGs for HOXA4 and 2 CpGs for FKBP5), using Bonferroni post hoc tests to examine the difference between
MTX and vitamin B12 concentrations on DNA methylation. A p-value of <0.05 was considered to be statistically
signiﬁcant for main effects of treatment, interaction and Bonferroni post hoc tests.
Results
Influence of MTX treatment & vitamin B12 concentration on cell proliferation
MTX exposure was not cytotoxic at either dose used within the time period of the experiment. However, both 1
and 5 μM MTX signiﬁcantly reduced proliferation of all cell lines when measured 3 days post-treatment compared
with untreated cells (Figure 3A) and therefore exerted a growth inhibitory effect. Vitamin B12 concentration also
signiﬁcantly inﬂuenced proliferation in all cell lines, with 10 ng/ml B12 reducing proliferation compared with both
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Figure 3. Effect of (A) MTX treatment (B) vitamin B12 concentration and (C) interaction between treatments on proliferation of DAOY,
SH-SY5Y and MO3.13 cells 4 days after seeding. Cells were seeded in T25 cm2 flasks at the following starting densities (total cell number):
MO3.13 and DAOY; 1 × 105 - SH-SY5Y - 2 × 105. Data were analyzed using univariate ANOVA, n = 9 per treatment group for main effects
(i.e., MTX and vitamin B12 treatments) and n = 3 for interaction, error bars represent 95% CIs. P-values relate to effect of treatment on
methylation; where groups do not share the same letter post hoc tests revealed significant differences (p > 0.05).
MTX: Methotrexate.
0 and 1 ng/ml treated cells (Figure 3B). No signiﬁcant interactions were observed between MTX treatment and
vitamin B12 concentrations for cell proliferation in any cell line investigated (Figure 3C).
Influence of MTX treatment on DNA methylation
MTX treatment increased LINE1 methylation in DAOY, SH-SY5Y and MO3.13 cells by 2.1, 1.2 and 0.8%
respectively across the dose range. These differences were found to be statistically signiﬁcant for DAOY and SH-
SY5Y (p < 0.001 and p = 0.040 respectively) but not MO3.13 (p = 0.102) (Figure 4A). In DAOY, methylation
was increased in response toMTX treatment compared with untreated cells, with post hoc tests revealing signiﬁcant
increases in methylation associated with low (1 μM) and high (5 μM) levels of MTX for all CpG sites investigated
(Figure 4A). In SH-SY5Y, methylation was also found to be increased in response to MTX treatment, although
post hoc tests did not suggest signiﬁcant differences between individual MTX treatment groups (Figure 4A).
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Figure 4. Effect of MTX treatment on (A) LINE1 (B) HOXA4 and (C) FKBP5 DNA methylation in DAOY, SH-SY5Y and MO3.13 cells. Data
were analyzed using univariate ANOVA, n = 9 per treatment group*, error bars represent 95% CIs. P-values relate to effect of treatment
on methylation; where groups do not share the same letter post hoc tests revealed significant differences (p > 0.05). (*with the exception
of HOXA4 methylation in MO3.13 cells where n = 7, 9 and 8 respectively for 0, 1 and 5 μM MTX groups).
MTX: Methotrexate.
HOXA4 methylation was decreased (by 0.7–0.8%) in DAOY, but increased in SH-SY5Y and MO3.13 cells
in response to MTX treatment (by 0.3–0.5 and 1.5–2.3% respectively), but these changes were not found to be
statistically signiﬁcant (Figure 4B).
FKBP5 methylation increased in response to MTX treatment in DAOY, SH-SY5Y and MO3.13, with 3.6,
2.7 and 2.8% increases in methylation between untreated and 1 μM MTX treated cells, respectively. However,
statistical signiﬁcance was only reached for MO3.13 cells (Figure 4C; p = 0.009), with post hoc tests revealing
signiﬁcant differences between 0 and 1 μM MTX treated cells (p = 0.008 for difference in methylation between
these two treatment groups), with no signiﬁcant difference in methylation between 0 and 5 or 1 and 5 μM treated
cells.
Influence of vitamin B12 concentration on DNA methylation
Changes in vitamin B12 concentration had little impact onmethylation changes across cell lines and loci investigated,
with only one statistically signiﬁcant increase in methylation observed at the HOXA4 loci in SH-SY5Y cells
(p = 0.029) (Table 2). Post hoc tests established a small signiﬁcant increase in methylation by 1.13% between 0
and 10 ng/ml treated cells.
Influence of an interaction between MTX treatment & vitamin B12 concentration on DNA
methylation
There was limited evidence to suggest an interaction between MTX and vitamin B12 treatments and altered DNA
methylation (data not shown). Only one signiﬁcant interaction between MTX and vitamin B12 treatments was
observed whereby in DAOY cells 10 ng/ml vitamin B12 appeared to be protective against MTX-associated LINE-1
methylation increases at 1 μM treatment, whereas both 1 and 10 ng/ml vitamin B12 concentrations increased
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Table 2. Methylation at all investigated loci in response to vitamin B12 treatment in DAOY, SH-SY5Y and MO3.13 cells.
Vitamin B12 concentration (ng/ml) Pooled SEM p-value
0 1 10
DAOY
Mean LINE1 methylation 40.67 40.97 40.72 0.164 0.414
Mean HOXA4
methylation
3.92 3.79 3.63 0.255 0.731
Mean FKBP5 methylation 81.00 84.15 83.10 1.205 0.198
SH-SY5Y
Mean LINE1 methylation 78.25 78.43 78.20 0.363 0.899
Mean HOXA4
methylation*
88.90a 89.20ab 90.03b 0.588 0.029
Mean FKBP5 methylation 91.34 90.39 89.42 1.159 0.514
MO3.13
Mean LINE1 methylation 77.22 77.09 76.73 0.272 0.436
Mean HOXA4
methylation
30.57 29.36 31.07 1.35 0.662
Mean FKBP5 methylation 92.55 92.31 92.73 0.569 0.873
Data were analyzed using univariate ANOVA, n = 9 or 8* per treatment group. P-values relate to effect of treatment on methylation; where groups do not share the same letter post hoc
tests revealed significant differences (p  0.05).
SEM: Standard error of the mean.
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Figure 5. Mean LINE1 methylation of DAOY treated with various concentrations of methotrexate and vitamin B12.
n = 3 per treatment group. Data were analyzed using univariate ANOVA, p = 0.038 for interaction between MTX and
vitamin B12 treatments. Error bars represent 95% CIs.
MTX: Methotrexate.
LINE-1 methylation in response to 5 μM MTX treatment (Figure 5). Given this ﬁnding was isolated; it may be
due to chance.
Discussion
MTX treatment has been associated with both acute [2] and long term [4,5] neurotoxicities in childhood leukemia
survivors, although the underlying mechanisms are not well understood. Evidence suggests that DNA methylation
may play an important role in the development of neurotoxicities associated with MTX treatment such as cognitive
impairment [10,23–25] and depression [26–29]. Therefore, given that MTX is known to inhibit dihydrofolate reductase,
thus reducing the production of SAM, which is critical for DNA methylation [30–32] and has been previously
proposed as a plausible mechanism for MTX toxicity [32], we hypothesize that DNA methylation patterns may
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be altered by MTX treatment and therefore may be a potential mediating mechanism between MTX treatment
and treatment-associated acute and long term neurotoxicities. As there is evidence that additional perturbations
to OCM may increase the risk of MTX-associated toxicities [3,8], we further propose that vitamin B12 levels may
inﬂuence the impact of MTX treatment on DNA methylation.
To investigate the plausibility of these hypothesizes, we tested the initial hypothesis thatMTX and B12 treatments
may have the potential to alter DNAmethylation in cell lines derived from cell populations whichmaybe relevant for
neurotoxicity. Using a 3× 3 factorial study design we treated neuronal and oligodendrocyte cell lines concomitantly
with low and high levels ofMTX and vitamin B12 and assessed global and site speciﬁc DNAmethylation in response
to the treatments individually and in combination.
In support of our initial hypothesis, we observed signiﬁcant increases in global DNA methylation (measured
using the LINE1 pyrosequencing assay) in DAOY and SH-SY5Y investigated in response to both low (1 μM)
and high (5 μM) levels of MTX treatment. While these changes were small (i.e., in the region of 1% increase),
they were statistically signiﬁcant, with the pattern of methylation change was consistent across the cell lines.
Similar small, signiﬁcant changes are commonly reported in studies investigating the inﬂuence of environment on
DNA methylation, and perhaps of more speciﬁc relevance, have been reported in response to MTX treatment in
blood samples of arthritic patients [14]. Furthermore, low level MTX treatment was associated with increased mean
methylation at the FKBP5 locus inMO3.13.While an increase inmethylation in response toMTX treatment, which
reduces available folate, seems paradoxical, this is in linewith previous reportedmodels ofmethyl donor depletion [33–
36] andMTX treatment [13–15,37,38]. As the folate, choline, methionine and vitamins B6 and B12 pathways are closely
connected, perturbations in one of these pathwaysmay plausibly lead to compensatory changes in others, whichmay
result in the observed paradoxical effect on DNA methylation. Indeed in support of this hypothesis, folate-induced
changes in methylation and gene expression have been previously observed to potentially inﬂuence one-carbon
metabolism and methylation pathways [35,36,39]. These data add to the currently limited evidence proposing MTX
treatment inﬂuences DNA methylation patterns, and suggest that MTX treatment is able to alter methylation
patterns in cell types derived from those likely to be key in the development of neurotoxicity.
Previously, both global DNA hyper- and hypomethylation have been associated withMTX treatment [14,15,37,38].
While global DNA hypomethylation has been observed in osteosarcoma cells treated with 1 and 40 μM MTX for
3 days in culture [37] and in embryonic neural tissue in a mouse model of MTX-induced neural tube defects [38],
global DNA hypermethylation has been observed in blood samples of arthritic patients treated withMTX compared
with untreated patients [14,15]. Here, we report increased methylation in response to low and high levels of MTX
treatment using LINE1 methylation as a measure of global DNA methylation. Although, there is limited evidence
for the inﬂuence of MTX treatment on gene speciﬁc methylation, Cribbs et al. reported reduced methylation of
the FOXP3 gene in cultured Treg cells [13], while Wang et al. reported 132 differentially methylated regions (35 low
methylated and 97 high methylated) in embryonic neural tissue of their MTX induced neural tube defects mouse
model [38]. We provide additional support for an effect of MTX treatment on DNA methylation at speciﬁc gene
loci, which may have implications for gene expression and therefore MTX-related toxicity. While in the current
study the implications of the altered methylation we report in response to MTX treatment in neuronal cells cannot
be determined in the context of acute and long-term neurotoxicities, it is plausible that the occurrence of these,
and other yet unobserved DNA methylation changes, could be a mediating mechanism leading to these, and other,
adverse events associated with this treatment.
It is important to note the use of cell lines was a limitation of this study. Malignant cells often express
folylpolyglutamate synthase, causing MTX to be metabolized to and retained within the cell as polyglutamates,
which may have affected the cell response to the MTX. As this does not occur in normal neural tissue this may
therefore limit the comparability of this model with normal cells. Furthermore, here cells were treated once with
MTX over a 3 day period, whereas clinical treatments regimens for childhood leukemia utilize multiple doses of this
drug given over time. Our 1 μM dose reﬂected a single intrathecal exposure at a clinically relevant concentration in
cerebrospinal ﬂuid (reported to be 1.1 ± 0.4 μM) [40]. However, it is highly plausible that DNAmethylation marks
that are susceptible to change via MTX exposure are likely to be cumulatively altered over the course of treatment
protocols, and therefore may exhibit ﬂuctuations in methylation change dependent on treatment dosing and other
environmental inﬂuences. Further knowledge of such cumulative changes during the course of treatment, including
whether they are sustained and long lasting, will be critical in understanding if and how DNA methylation plays
a role in the development of both acute and long term neurotoxicity associated with the treatment of childhood
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leukemia. Therefore, exploring intermittent exposures to lower concentrations of MTX will be important in future
studies.
We proposed that vitamin B12 levels may inﬂuence the impact ofMTX treatment onDNAmethylation; however
our data provide limited evidence in support of this hypothesis. While HOXA4 methylation increased in response
to 10 ng/ml vitamin B12 compared with 0 ng/ml vitamin B12 in SH-SY5Y cells, and a signiﬁcant interaction was
observed between MTX and vitamin B12 treatment in DAOY cells, we observed no further evidence that vitamin
B12 concentration alone or in combination with MTX altered DNA methylation, which may suggest that these
observations were chance ﬁndings.
However, it is pertinent to highlight that this preliminary study was restricted in its assessment of DNA
methylation markers which is likely to have limited the likelihood of observing methylation changes in response
to treatment. Indeed, previous studies have observed global and site-speciﬁc methylation changes in response
to vitamin B12 concentrations [41,42] and therefore further investigations are warranted to examine the potential
interactions between one carbon moieties, MTX treatment and subsequent effects of DNA methylation for acute
and long-term neurotoxicities.
The use of dialyzed FBS was vital for our investigation, as small molecules under 10 kDa such as vitamin B12 are
removed from the media. However, inevitably other small molecules involved in OCM are also removed during
this process (i.e., vitamin B2 [riboﬂavin], vitamin B6, folate and choline). We therefore used basal DMEM high
glucose media to culture cells, as it lacks vitamin B12, but importantly contains these other vital OCM components;
folic acid, riboﬂavin, vitamin B6 (in the form of pyridoxine hydrochloride) and choline (in the form of choline
chloride). Hence, considering OCM is a complex process involving many small molecules, we cannot guarantee
that use of dialyzed FBS and our chosen media formulation has provided physiologically relevant levels of all
of these components, but suggests that our experimental design has ensured that the major components are all
present, excepting vitamin B12. Indeed, we recognize that in particular concentrations of folic acid in the culture
medium are supraphysiological (approx. 9 μM) as opposed to the normal range of plasma folate (2–21 nmol/L
5-MTHF). While the difference in form and levels of folate may inﬂuence the interpretation of these data in a
clinical context, particularly given that folate deﬁciency is common in childhood leukemia patients, it is important
to note that folate concentrations were uniform across experiments performed. Therefore, while it is plausible
that both MTX and B12 treatments may inﬂuence DNA methylation differently in the context of physiological
folate concentrations, we would hypothesize that it is likely that overall baseline methylation levels will be altered
or responses to these treatments be exacerbated, rather than changed per se. It is important to note that for the
duration of the experiment, all cell lines used experienced no negative effects on proliferation by culturing in dFBS
compared with nondialyzed FBS typically recommended for the culture of these cell lines (data not shown).
In addition to investigating altered DNA methylation in response to MTX and vitamin B12, we monitored cell
proliferation in response to these treatments. Given the cytotoxic nature of MTX, as expected both physiological
relevant and high levels of treatment led to signiﬁcant limitation of growth proliferation in both neuronal and
oligodendrocyte cell lines. Perhaps unexpected was the observation that high doses (i.e., 10 ng/ml) of vitamin
B12 reduced proliferation in all cell lines. We would suggest that this response may be due to exposure to supra-
physiological levels of vitamin B12 which would not usually be encountered by these cell types in vivo due to
regulation of circulating vitamin B12 levels by the liver.
Conclusion
Here, we provide evidence in support of our hypothesis that altered methylation may potentially act as a mediating
mechanism between MTX treatment and subsequent neurotoxicities, however currently the evidence is limited
to support our suggestion that altered B12 concentrations may further inﬂuence the impact of MTX treatment
on this potential mechanism. Our results are limited in investigating three cell lines, but suggest that alteration
of methylation in different neural cell types at concentrations of MTX known to be reached in the cerebrospinal
ﬂuid of patients undergoing leukemia treatment [43] might be affected by MTX treatment. While the use of cell
lines as opposed to human tissues is a limitation of this study, this approach was warranted in the ﬁrst instance to
provide proof of principle where availability of human samples are lacking (i.e., in order to determine the effect of
treatment in human tissues samples collected before and after treatment would be required, in this case unethical
and invasive biopsies of neural tissue).
Here, we measured DNA methylation using one global proxy measure and two gene loci. In order to fully
elucidate the relationship between MTX, DNA methylation and neurotoxicity risk, further detailed knowledge of
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the effects of MTX and the interaction between drug treatment and various aspects of OCM (including levels of
vitamin B12, folate and choline) on DNA methylation patterning is warranted. The utilization of genome-wide
methylation assessments in vitro (preferably iPSC/ESC derived nonmalignant neural or primary cells as models
of normal cells as opposed to tumor-derived cell lines) and animal model studies will be critical in understanding
these mechanistic processes and interactions where relevant human tissue samples are not available or practicable.
Such investigations will inform future molecular epidemiological investigations involving patients undergoing
treatment and long-term cancer survivors to examine the potential role of key DNA methylation marks and
aspects of OCM in MTX-associated acute and late neurotoxcities. The outcomes of these studies may have clinical
relevance, including the potential for monitoring of one carbon moieties during MTX treatment of childhood
leukemia patients to identify individuals at high risk of developing acute toxicity, or the development of robust
DNA methylation biomarkers to predict acute and/or long-term toxicities. As improved treatments for childhood
leukemia are leading to increasing survival rates [44], such future research is highly justiﬁed in order to aid reﬁning
of therapies and to identify high risk individuals for intervention treatments to reduce long-term adverse effects of
treatment. These investigations will also provide valuable data resource to inform studies in other patients groups
treated with MTX such as numerous adult cancer types and arthritis sufferers.
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Summary points
Background
 Methotrexate (MTX) is an antifolate drug used to treat pediatric acute lymphoblastic leukemia and works by
reducing levels of tetrahydrofolate via inhibition of dihydrofolatereductase, hence interrupting one carbon
metabolism and interfering with DNA synthesis and methylation.
 MTX treatment in acute lymphoblastic leukemia has been associated with acute and chronic neurotoxicity and it
has been proposed that levels of other factors involved in one carbon metabolism such as vitamin B12 may
influence the risk of neurotoxicity.
 The use of nitrous oxide in sedation during or shortly prior to administration of MTX may contribute to the risk
of severe acute neurological side effects in children via the depletion of vitamin B12.
 Altered methylation via depletion of S-adenosyl methionine has been suggested to have an impact on
myelination, providing one possible mechanism for neurotoxicity after methotrexate treatment.
Influence of MTX treatment & vitamin B12 concentration on cell proliferation
 MTX exposure was not cytotoxic at 1 and 5 μM doses within the experimental time period of 3 days, however
both doses significantly reduced proliferation of all cell lines.
 High doses (10 ng/ml) of vitamin B12 reduced proliferation of all cell lines.
Influence of MTX treatment &/or B12 treatment on DNA methylation
 MTX treatment alone significantly increased LINE-1 methylation in SH-SY5Y (p = 0.040) and DAOY (p < 0.001),
but not MO3.13 cells, and increased FKBP5 methylation in MO3.13 cells (p = 0.009).
 While these changes were small (i.e., in the region of 1% increase), they were statistically significant, with the
pattern of methylation change being consistent across the cell lines.
 Similar small, significant changes are commonly reported in studies investigating the influence of environment
on DNA methylation, and perhaps of more specific relevance, have been reported in response to MTX treatment
in blood samples of arthritic patients.
 There was limited evidence for an effect of vitamin B12 concentration alone or in combination with MTX
treatment on DNA methylation within the confines of this study.
Conclusion
 Neurotoxicity is a worrying acute side effect of childhood leukemia treatment.
 Long-term neurocognitive deficits are increasingly observed in survivors, with MTX implicated as the main
causative agent.
 Altered methylation may act as a mediating mechanism between MTX treatment and subsequent neurotoxicities.
 Currently the evidence is limited to support our suggestion that altered B12 concentrations may further influence
the impact of MTX treatment on this potential mechanism.
 Our results suggest methylation is altered in different neural cell types at concentrations of MTX known to be
reached in the cerebrospinal fluid of patients undergoing leukemia treatment.
 Future work on this topic should include the utilization of genome-wide methylation assessments in vitro such as
induced-pluripotent or embryonic stem cells and animal model studies.
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1 Mckay JA, Mathers JC. Diet induced epigenetic changes and their implications for health. Acta Physiol. (Oxf.) 202(2), 103–118 (2011).
2 Dufourg MN, Landman-Parker J, Auclerc MF et al. Age and high-dose methotrexate are associated to clinical acute encephalopathy in
FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 21(2), 238–247 (2007).
3 Lobel U, Trah J, Escherich G. Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute
lymphoblastic leukemia. Pediatr. Blood Cancer 62(3), 539–541 (2015).
•• Clinical case report implying concomitant use of nitrous oxide and methotrexate in severe neurotoxicity.
4 Cheung YT, Krull KR. Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on
contemporary treatment protocols: A systematic review. Neurosci. Biobehav. Rev. 53, 108–120 (2015).
• Comprehensive review of long-term neurocognitive outcomes of survivors of childhood leukemia.
5 Van Der Plas E, Nieman BJ, Butcher DT et al. Neurocognitive late effects of chemotherapy in survivors of acute lymphoblastic leukemia:
focus on methotrexate. J. Can. Acad. Child Adolesc. Psychiatry 24(1), 25–32 (2015).
6 Forster VJ, Van Delft FW, Baird SF, Mair S, Skinner R, Halsey C. Drug interactions may be important risk factors for methotrexate
neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother. Pharmacol. 78(5), 1093–1096 (2016).
•• Overview of potential drug interactions that may inﬂuence methotrexate toxicity in childhood acute lymphoblastic leukemia
patients.
1216 Epigenomics (2017) 9(9) future science group
Methotrexate induces changes in DNA methylation Research Article
7 Kroes AC, Lindemans J, Schoester M, Abels J. Enhanced therapeutic effect of methotrexate in experimental rat leukemia after
inactivation of cobalamin (vitamin B12) by nitrous oxide. Cancer Chemother. Pharmacol. 17(2), 114–120 (1986).
8 Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their
association with methotrexate toxicity: a meta-analysis. Pharmacogenet. Genomics 22(2), 117–133 (2012).
9 Mathers JC, Strathdee G, Relton CL. Induction of epigenetic alterations by dietary and other environmental factors. Adv. Genet. 71,
3–39 (2010).
10 Rudenko A, Tsai LH. Epigenetic modiﬁcations in the nervous system and their impact upon cognitive impairments. Neuropharmacology
80, 70–82 (2014).
11 Varela-Rey M, Iruarrizaga-Lejarreta M, Lozano JJ et al. S-adenosylmethionine levels regulate the schwann cell DNA methylome. Neuron
81(5), 1024–1039 (2014).
12 Landgrave-Gomez J, Mercado-Gomez O, Guevara-Guzman R. Epigenetic mechanisms in neurological and neurodegenerative diseases.
Front. Cell. Neurosci. 9, 58 (2015).
13 Cribbs AP, Kennedy A, Penn H et al. Methotrexate restores regulatory T cell function through demethylation of the FoxP3 upstream
enhancer in patients with rheumatoid arthritis. Arthritis Rheumatol. (Hoboken, N.J.) 67(5), 1182–1192 (2015).
14 De Andres MC, Perez-Pampin E, Calaza M et al. Assessment of global DNA methylation in peripheral blood cell subpopulations of early
rheumatoid arthritis before and after methotrexate. Arthritis Res. Ther. 17, 233 (2015).
15 Kim YI, Logan JW, Mason JB, Roubenoff R. DNA hypomethylation in inﬂammatory arthritis: reversal with methotrexate. J. Lab. Clin.
Med. 128(2), 165–172 (1996).
16 Bollati V, Baccarelli A, Hou L et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 67(3),
876–880 (2007).
17 Strathdee G, Sim A, Parker A, Oscier D, Brown R. Promoter hypermethylation silences expression of the HoxA4 gene and correlates
with IgVh mutational status in CLL. Leukemia 20(7), 1326–1329 (2006).
18 Van Otterdijk SD, Norden J, Dickinson AM et al. Aberrations in DNA methylation are detectable during remission of acute
lymphoblastic leukemia and predict patient outcome. Epigenomics 7(1), 35–45 (2015).
• Indication of altered methylation after treatment for pediatric leukemia.
19 Klengel T, Mehta D, Anacker C et al. Allele-speciﬁc FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat.
Neurosci. 16(1), 33–41 (2013).
20 Bagur J, Massoubre C, Casagranda L, Faure-Conter C, Trombert-Paviot B, Berger C. Psychiatric disorders in 130 survivors of childhood
cancer: preliminary results of a semi-standardized interview. Pediatr. Blood Cancer 62(5), 847–853 (2015).
21 Kunin-Batson AS, Lu X, Balsamo L et al. Prevalence and predictors of anxiety and depression after completion of chemotherapy for
childhood acute lymphoblastic leukemia: a prospective longitudinal study. Cancer 122(10), 1608–1617 (2016).
22 Prasad PK, Hardy KK, Zhang N et al. Psychosocial and neurocognitive outcomes in adult survivors of adolescent and early young adult
cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 33(23), 2545–2552 (2015).
• Discussion of neurocognitive and psychosocial outcomes in childhood leukemia survivors.
23 Jones MJ, Farre P, Mcewen LM et al. Distinct DNA methylation patterns of cognitive impairment and trisomy 21 in down syndrome.
BMC Med. Genomics 6, 58 (2013).
24 Lazarus J, Mather KA, Armstrong NJ et al. DNA methylation in the apolipoprotein-A1 gene is associated with episodic memory
performance in healthy older individuals. J. Alzheimers Dis. 44(1), 175–182 (2015).
25 Marioni RE, Shah S, Mcrae AF et al. The epigenetic clock is correlated with physical and cognitive ﬁtness in the Lothian Birth Cohort
1936. Int. J. Epidemiol. 44(4), 1388–1396 (2015).
26 Lockwood LE, Su S, Youssef NA. The role of epigenetics in depression and suicide: a platform for gene-environment interactions.
Psychiatry Res. 228(3), 235–242 (2015).
27 Murphy TM, O’donovan A, Mullins N, O’Farrelly C, Mccann A, Malone K. Anxiety is associated with higher levels of global DNA
methylation and altered expression of epigenetic and interleukin-6 genes. Psychiatr. Genet. 25(2), 71–78 (2015).
28 Nagy C, Suderman M, Yang J et al. Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. Mol.
Psychiatry 20(3), 320–328 (2015).
29 Tseng PT, Lin PY, Lee Y et al. Age-associated decrease in global DNA methylation in patients with major depression. Neuropsychiatr. Dis.
Treat. 10, 2105–2114 (2014).
30 Varela-Moreiras G, Ragel C, Perez De Miguelsanz J. Choline deﬁciency and methotrexate treatment induces marked but reversible
changes in hepatic folate concentrations, serum homocysteine and DNA methylation rates in rats. J. Am. Coll. Nutr. 14(5), 480–485
(1995).
31 Vezmar S, Schusseler P, Becker A, Bode U, Jaehde U. Methotrexate-associated alterations of the folate and methyl-transfer pathway in
the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr. Blood Cancer 52(1), 26–32 (2009).
future science group www.futuremedicine.com 1217
Research Article Forster, McDonnell, Theobald & McKay
•• Presents evidence for the effect of methotrexate on the folate and methyl transfer pathway in cerebrospinal ﬂuid of pediatric
leukemia patients with and without neurotoxicity.
32 Wang YC, Chiang EP. Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo. Mol. Med. 18, 423–432
(2012).
• Presents evidence of the effect of methotrexate on S-adenosyl methionine and discusses potential impact on methylation
processes.
33 Bermingham EN, Bassett SA, Young W et al. Post-weaning selenium and folate supplementation affects gene and protein expression and
global DNA methylation in mice fed high-fat diets. BMC Med. Genomics 6, 7 (2013).
34 Cordero P, Campion J, Milagro FI, Martinez JA. Transcriptomic and epigenetic changes in early liver steatosis associated to obesity:
effect of dietary methyl donor supplementation. Mol. Genet. Metab. 110(3), 388–395 (2013).
35 Mckay JA, Adriaens M, Evelo CT, Ford D, Mathers JC. Gene promoter DNA methylation patterns have a limited role in orchestrating
transcriptional changes in the fetal liver in response to maternal folate depletion during pregnancy. Mol. Nutr. Food Res. 60(9),
2031–2042 (2016).
36 Mckay JA, Xie L, Adriaens M, Evelo CT, Ford D, Mathers JC. Maternal folate depletion during early development and high fat feeding
from weaning elicit similar changes in gene expression, but not in DNA methylation, in adult offspring. Mol. Nutr. Food Res. 61(4),
1600713 (2017).
37 Sramek M, Neradil J, Sterba J, Veselska R. Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations
and enhanced cell differentiation. Cancer Cell Int. 16, 14 (2016).
38 Wang X, Guan Z, Chen Y et al. Genomic DNA hypomethylation is associated with neural tube defects induced by methotrexate
inhibition of folate metabolism. PLoS ONE 10(3), e0121869 (2015).
39 Mckay JA, Xie L, Adriaens M, Evelo CT, Ford D, Mathers JC. Organ-speciﬁc gene expression changes in the fetal liver and placenta in
response to maternal folate depletion. Nutrients 8(10), 661 (2016).
40 Evans WE, Hutson PR, Stewart CF et al. Methotrexate cerebrospinal ﬂuid and serum concentrations after intermediate-dose
methotrexate infusion. Clin. Pharmacol. Ther. 33(3), 301–307 (1983).
41 Mckay JA, Groom A, Potter C et al. Genetic and non-genetic inﬂuences during pregnancy on infant global and site speciﬁc DNA
methylation: role for folate gene variants and vitamin B12. PLoS ONE 7(3), e33290 (2012).
42 Kok DE, Dhonukshe-Rutten RA, Lute C et al. The effects of long-term daily folic acid and vitamin B12 supplementation on
genome-wide DNA methylation in elderly subjects. Clin. Epigenetics 7, 121 (2015).
43 Niemann A, Muhlisch J, Fruhwald MC, Gerss J, Hempel G, Boos J. Therapeutic drug monitoring of methotrexate in cerebrospinal ﬂuid
after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced? Ther. Drug Monit. 32(4), 467–475
(2010).
44 Moorman AV, Enshaei A, Schwab C et al. A novel integrated cytogenetic and genomic classiﬁcation reﬁnes risk stratiﬁcation in pediatric
acute lymphoblastic leukemia. Blood 124(9), 1434–1444 (2014).
1218 Epigenomics (2017) 9(9) future science group
